Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

当43岁主持人金昀骤然离世的新闻刷屏，一个陌生医学术语引发公众关注——​​肺动脉高压（PH）​​。这种被称作"心肺桥梁崩塌"的疾病，每年吞噬数十万生命。想象一下，身体里有一根连接心脏和肺脏的“生命管道”，负责把全身缺氧的血液送到肺部去“充氧”。如果这 ...

肺动脉高压是一种以肺动脉压力持续升高为特征的严重肺血管疾病，临床上，常用血管舒张剂来缓解症状和降低血流阻力，但针对肺血管重塑这一病变核心环节，目前尚缺乏有效的治疗手段。免疫疗法作为近年来兴起的重要治疗策略，逐渐显示出在肺动脉高压治疗中的潜力。

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release ...

未经治疗的中重度肺动脉高压患者的五年生存率低于50%，这一数据凸显了及时诊断和积极治疗的重要性。肺动脉高压的高死亡率主要归因于疾病的进展性和复杂性。患者需要长期接受治疗，并且需要定期监测和调整治疗方案。此外，高昂的医疗费用和心理压力也是患者面临的重要挑战。

Merck (NYSE:MRK) said on Monday that its late-stage study, testing Winrevair in adults with moderate to high risk pulmonary ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Shares of Insmed (INSM) jumped nearly 30% Tuesday after the biopharmaceutical company reported positive results from a Phase ...